Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

NCT00807170 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Very slow recruitment

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: ZD6474 (Vandetanib)
RADIATION: Whole Brain Radiotherapy (WBRT)
DRUG: ZD6474
DRUG: ZD6474

Sponsor

Sanofi